
|Articles|May 1, 2005
How to treat refractory OAB using injectable botulinum toxin
No patient has developed urinary retention or elevated post-void residuals following our modified injection technique.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
BOND-003 Cohort C: Efficacy Results
4
Individualizing androgen pathway therapy in mCSPC
5








